Who Owns Gardasil?

Gardasil operates under Merck's corporate sustainability framework, which addresses environmental responsibility, ethical business practices, and global health access.

Merck has committed to achieving net-zero greenhouse gas emissions across all operations (Scopes 1, 2, and 3) by 2045, aligned with Science Based Targets initiative (SBTi) guidelines. The company aims to reduce emissions by 30% by 2030 from 2019 baseline levels and source 100% of purchased electricity from renewable sources. Gardasil manufacturing facilities participate in these corporate environmental initiatives through energy efficiency improvements, water conservation programs, and waste reduction efforts.

Water conservation is a critical concern for vaccine manufacturing. Merck maintains water risk assessments and implements water conservation technologies across its production network. Gardasil production facilities utilize water recycling systems and efficient cooling technologies to minimize environmental impact.

Global health access is a central component of Gardasil's ethical framework. Merck partners with Gavi, the Vaccine Alliance, and UNICEF to provide Gardasil doses at significantly reduced prices to low- and middle-income countries with high cervical cancer burdens. These partnerships have enabled the expansion of HPV vaccination programs in developing countries where cervical cancer rates are highest. The World Health Organization's cervical cancer elimination goals rely on increased HPV vaccine access in these regions.

Merck has implemented tiered pricing strategies for Gardasil, charging higher prices in high-income countries and significantly lower prices in low-income countries. The company has faced criticism regarding Gardasil's pricing in middle-income countries that do not qualify for Gavi support but still have high cervical cancer rates.

Gardasil's clinical development and post-marketing surveillance programs include independent data monitoring committees, transparent reporting of adverse events, and continuous safety assessment. The vaccine's clinical trial program involved over 29,000 participants across multiple studies.

Gardasil has received significant recognition as one of the most important public health achievements of the 21st century.

• Prix Galien USA Award (2007): Gardasil received the Prix Galien USA Award for Best Biotechnology Product, often considered the equivalent of the Nobel Prize for pharmaceutical research. The award recognized Gardasil's innovative approach to cancer prevention through immunization.
• Public Health Impact Recognition: The development of the HPV vaccine has been acknowledged by the World Health Organization, the Centers for Disease Control and Prevention, and numerous national health ministries as a transformative advance in cancer prevention. The WHO has set cervical cancer elimination as a global public health target, with HPV vaccination as a key strategy.
• Research Recognition: The scientific research behind Gardasil's development, particularly the virus-like particle technology developed by Professor Ian Frazer and Dr. Jian Zhou, has been recognized by medical research organizations and academic institutions worldwide. Professor Frazer was named Australian of the Year in 2006 for his contributions to cervical cancer prevention.
• Global Health Equity Recognition: Gardasil's role in global health initiatives through partnerships with Gavi and UNICEF has received recognition for expanding HPV vaccination access in low- and middle-income countries.

Safety Litigation (Ongoing): Merck faces numerous lawsuits consolidated in multidistrict litigation (MDL) from plaintiffs alleging that Gardasil caused autoimmune disorders and other severe side effects. Plaintiffs claim Merck concealed these risks. In early 2025, Merck successfully defeated several bellwether claims when a federal judge ruled that the plaintiffs' expert testimony linking the vaccine to certain conditions was scientifically unreliable. However, litigation continues.

2013 Voluntary Recall: In December 2013, Merck initiated a voluntary recall of one specific lot of Gardasil due to the potential for a small number of vials to contain glass particles from a manufacturing issue. The CDC and FDA noted the health risk was extremely low. No injuries were reported.

Aggressive Marketing and Lobbying (2006-2007): Following FDA approval in 2006, Merck launched an aggressive marketing campaign and lobbied for state-level mandatory vaccination requirements for school-age girls. The lobbying campaign drew criticism from medical ethicists, public health advocates, and parent groups. A 2007 editorial in Nature Biotechnology criticized Merck's marketing tactics, including fear-based advertising slogans. Merck announced a cessation of lobbying efforts for compulsory vaccination laws in 2007.

Vaccine Hesitancy: Gardasil has been a target of anti-vaccine advocacy groups, including Children's Health Defense, which have amplified safety concerns and criticized the vaccine's development and marketing processes. These campaigns have contributed to vaccine hesitancy in some populations, affecting vaccination rates.

China Market Downturn (2024-2025): Gardasil sales in China declined significantly beginning in Q2 2024 due to weak discretionary spending, reduced promotional activity related to anti-corruption concerns, and inventory adjustments by Merck's Chinese distributor. Merck paused shipments to China in February 2025 through at least mid-year, contributing to a 39% decline in global Gardasil sales for 2025. The company pulled Gardasil's long-term sales target, and shares tumbled 11% on the announcement.

Pricing and Access Concerns: Gardasil has faced criticism regarding its pricing and accessibility, particularly in middle-income countries that do not qualify for Gavi support but still have high cervical cancer rates. Questions about vaccine affordability have led to discussions about pricing strategies and global health equity.